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Objective: This report describes the pilot of a free comprehensive national screening program for venous disease.
Methods: The screening process consisted of a venous thromboembolism (VTE) risk assessment, abbreviated duplex
examination for venous obstruction and reflux, inspection for signs of chronic venous insufficiency (CVI), and an exit
interview. Physicians coordinating the screenings were members of the American Venous Forum.
Results: Seventeen institutions screened 476 people (mean, 28 per site; range, 6 to 71). Mean age was 60 years (range, 40
to 91 years), with 78% women and 68% with a body mass index of >25. If placed in a situation conducive for VTE, 22
participants (5%) were low risk, 87 (18%) were moderate risk, 186 (39%) were high risk, and 179 (38%) were at very high
risk. In 26 people (6%), one or more segments had venous obstruction, and 190 (40%) had one or more segments of
venous reflux in the lower extremities. Varicose veins were present in 32%, edema without skin changes in 11%, skin
changes attributable to venous disease in 8%, and healed or active venous stasis ulcer in 1.3% (CEAP classification 2, 3, 4,
5, and 6, respectively). Increasing age and increasing deep venous thrombosis risk score significantly correlated with
increasing clinical classification, r  0.09, P  .04, and r  0.16, P  .0004, respectively. Those participants with reflux
in one or more segments were significantly more likely to have a higher clinical classification compared with those with no
reflux (P  .0001).
Conclusion: The first comprehensive national screening for venous disease was performed. Participants were informed of
their risk for VTE if placed in a situation conducive to VTE, screened for evidence of obstruction, reflux, and CVI, and
empowered to share their results with their primary care provider. ( J Vasc Surg 2007;45:142-8.)The two most common manifestations of venous dis-
ease include venous thromboembolism (VTE) and chronic
venous insufficiency (CVI). Statistics are staggering when
evaluating the consequences of VTE: 1 in 20 people will be
diagnosed with VTE over a lifetime.1-3 VTE is responsible
for600,000 hospital admissions per year, and pulmonary
embolism is the third most common cause of hospital
death. Similarly,6million individuals in theUnited States
have severe symptoms from CVI that range from skin
changes to recalcitrant ulcers in the gaiter area. Other less
morbid but clinically relevant manifestations of CVI, such
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142as varicose veins, are estimated to afflict24 million Amer-
icans.4,5
Considering the scope of venous disease, public aware-
ness remains paramount to the possibility of improving
outcomes of prevention, identification, and treatment. In
addition, all specialties of clinical medicine may benefit
from improvements in VTE and CVI education. Previous
reports have documented difficulties by physicians in pro-
viding adequate VTE prophylaxis during high-risk situa-
tions as well as early diagnosis and proper treatment for
CVI.6-8
Many public screening programs have been imple-
mented with the goal of early disease detection.9-11 En-
hanced public awareness and education of physicians may
be further improved by these programs. In this article, the
American Venous Forum reports on the mission of provid-
ing a free comprehensive national screening program that
educates about VTE, varicose veins, and CVI; identifies
those at risk for VTE; examines for venous obstruction or
reflux, or both; inspects for the presence of CVI; and
empowers those screened to inform their physician of their
risk or presence of venous disease.
METHODS
The decision to embark on a public screening program
for venous disease was made by the Executive Council of
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ton, DC, in September 2004. An Ad hoc Venous Screen-
ing Committee was formed to develop a preliminary
screening instrument and begin dialogue with the Arte-
rial Screening Program of the American Vascular Associ-
ation. During the Seventeenth Annual Meeting of the
American Venous Forum in February 2005, representatives
from the Ad hoc Venous Screening Committee and the
American Vascular Association refined the screening instru-
ment using themodel of the American Vascular Association
Arterial Screening Program.12 The American Venous Fo-
rum Executive Council voted unanimously to move for-
ward with the screening program and formed a National
Venous Screening Committee. Funding for the program
was overseen by the American Venous Forum, while the
development of the screening program moved in partner-
ship with the American Vascular Association.
National Venous Screening Week was designated to be
from November 7 to 12, 2005, approximately 6 months
after the national American Vascular Association Arterial
Screening Program. Before the screening in November,
tasks completed to develop the program included:
● testing the preliminary screening instrument at three
institutions (coauthors: J. M. L., F. T. P., and T. W. W.)
during the AmericanVascular Association arterial screen-
ing in May 2005;
● further refinement and completion of the screening
instrument;
● developing a screening tool kit;
● writing educational brochures concerning VTE, vari-
cose veins, and CVI;
● identifying sites desiring to participate in the venous
screening; and
● designing, printing, collating, and distributing venous
screening materials.
The screening process included self-completion of the
demographic questionnaire and VTE risk assessment, an
abbreviated duplex examination for venous reflux and ob-
struction of the lower extremities, inspection by a trained
professional or physician to classify the lower extremities
using the CEAP classification system,13 and an exit inter-
view with a venous report card given to the person being
screened (Appendix I,A and I, B, online only). Participants
were also asked to sign a release form.
The VTE risk assessment was designed to evaluate a
person’s risk of developing VTE if put into a high-risk
situation. A high-risk situation was defined on the report
card as a surgical procedure, major injury or other hospital-
izations, malignancy, or prolonged immobility. The VTE
risk assessment, developed by Caprini et al,14 has been
based on retrospective incidence data and is beyond the
scope of this report. Briefly, point scores based on the
severity of the VTE risk factor are assigned and totaled for
a final score. VTE risk if placed in a high-risk situation was
then categorized as low risk (0% to 0.4%), moderate risk
(0.5% to 4%), high risk (5% to 10%), and very high risk (10%to 20%). Total points needed for each risk category were 0
to 1, 2, 3 to 4, and 4, respectively.
The abbreviated duplex ultrasound examination con-
sisted of bilateral insonation of the common femoral vein
(CFV), saphenofemoral junction (SFJ), and the above knee
popliteal vein. With the person in the supine position and
the head of bed elevated 30°, Valsalva was performed at
each vein location to evaluate for reversal of flow 0.5
seconds. B-mode was used to evaluate compression of the
vein segments in the same locations for any signs of ob-
struction. Obstruction was defined as inability to oppose
the walls of the insonated segments by manual compression
of the probe owing to an acute or chronic deep venous
thrombosis (DVT).
The AVF screening committee recommended that all
sonographers at screening sites be registered vascular tech-
nologists and that screening sites be accredited with Inter-
societal Committee for the Accreditation of Vascular Lab-
oratories. The recommended technique to perform duplex
scanning was outlined in the National Venous Screening
Tool Kit that was provided to all sites.
Lower extremities were inspected in the standing posi-
tion by a trained professional or physician to assess for
severity of class in the CEAP system.13 After inspection,
participants had an exit interview to briefly discuss the
findings of their screening and receive a report card with a
summary of the results. They were encouraged to share the
results with their primary care physicians or family doctors.
Each person screened also received three educational bro-
chures with information in laymen’s language about DVT,
CVI, and varicose veins. Data collected remained anony-
mous and were forwarded to the American Vascular Asso-
ciation. All data were entered into a database created by
Access (Microsoft Corp, Redmond, Wash).
Members of the American Venous Forumwere notified
by e-mail of the opportunity to participate in the national
pilot screening program. Volunteer sites were notified that
November 7 to 12, 2005, would be designated as National
Venous Screening Week. Sites were allowed leeway to
screen after this week. All sites received a National Venous
Screening Tool Kit giving detailed instructions about mar-
keting, preparation, and completing the screening process.
Individuals to be targeted for the screening were at the
discretion of the screening site. A general recommendation
was made to target the general public who were aged 40
years.
The statistical software SAS 9.1 (SAS Institute Inc,
Cary, NC) was used for all analyses. Independent groups
t tests were used to compare groups of patients by the
presence or absence of obstruction or reflux. Variables
compared included age, body mass index (BMI), and risk
score. Fisher’s exact test or 2 tests of independence, as
appropriate, were used to examine the relationship of the
presence or absence of these findings with the demographic
and medical history variables. The 2 tests of independence
were also used to examine the relationship of risk category
with the previously mentioned variables.
g in t
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maximum clinical classification by gender, race, diabetes,
high blood pressure, heart failure, smoking status (ever vs
never), use of blood thinner, use of aspirin, presence or
absence of obstruction in either leg, reflux in either leg, and
reflux in either leg of the CFV, SFJ and popliteal veins.
Spearman correlation coefficients were used to examine the
relationship between maximum clinical classification and
age, BMI, andDVT risk score.Multivariate analysis was not
performed owing to low numbers of significant findings in
the univariate analyses for each major group comparisons.
Major group comparisons included VTE risk factors, du-
plex examination for obstruction and reflux in venous
segments, and CEAP classification in each lower limb. P 
.05 was considered statistically significant.
RESULTS
Seventeen institutions screened 476 people (mean, 28
per site; range, 6 to 71 per site). Fig 1 shows the geographic
distribution of the screening sites. Appendix II (online
only) lists each screening institution, location, and primary
designate. Table I lists basic demographic data and medical
information of the screened population. Forty-five percent
of participants indicated their doctor was a family practitio-
ner, 40% indicated an internist, and 12% indicated another
specialty. Reasons for coming to be screened included 43%,
varicose veins; 36%, free screening; 13%, swollen leg; 3%,
“blood clot”; 2%, cosmetic problem; and 1%, other reason.
Table II lists data showing the number of participants
who gave affirmative answers for each risk factor for DVT.
Fig 2 shows the distribution of total point scores for the
population screened. When considering the DVT risk if
placed in a high-risk situation, 22 participants (5%) were
low risk, 87 (18%) were moderate risk, 186 (39%) were
Fig 1. Geographic distribution of 17 centers participatinhigh risk, and 179 (38%) were at very high risk.Table III shows the distribution of obstruction and
reflux discovered in the CFV, SFJ, and popliteal vein of
each leg. In 26 people (6%), one or more segments of
obstruction were present, and 190 (40%) people had one or
more segments of reflux.
Table IV shows the distribution of clinical class for CVI
for each extremity. When individuals were examined for
signs of CVI as opposed to left or right limb, varicose veins
were present in 32%, edema without skin changes in 11%,
skin changes attributable to venous disease in 8%, and
healed or active venous stasis ulcer in 1.3%.
When the demographic data (eg, male vs female), med-
he National Pilot Screening Program for Venous Disease.
Table I. Demographic and medical information on 476
people participating in the National Pilot Screening
Program in Venous Disease
Variable Mean (range)
Age (years) 60 (26-91)
Body mass index 28 (16-51)
Number (%)
Female 373 (78)
Male 100 (22)
Caucasian 392 (84)
African American 36 (8)
Diabetes mellitus 33 (7)
Hypertension 153 (31)
Congestive heart failure 12 (2)
Nonsmoker 249 (57)
Smoker 24 (5)
Past smoker 168 (38)
Aspirin 103 (21)
Clopidogrel 8 (2)
Warfarin 25 (5)ical information (eg, hypertension vs no hypertension), and
affirm
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participants with or without obstruction was compared, no
significant differences were noted. The only significant
difference when making similar comparisons with the pres-
ence or absence of valvular reflux demonstrated that smok-
ers were significantly more likely to have no reflux in one or
both legs compared with nonsmokers (P  .03).
Several significant differences were noted when com-
parisons were made among different cohort groups for
reflux vs no reflux in individual venous segments. Partici-
pants with hypertension were significantly less likely to have
CFV reflux compared with nonhypertensive individuals
(P  .03). Those participants with reflux of the SFJ had a
significantly higher risk factor point score (mean, 4.7)
compared with those without reflux (mean, 4.0; P  .01).
Similarly, those participants with reflux of the popliteal vein
had a significantly higher risk factor point score (mean, 4.9)
compared with those without reflux (mean, 4.1; P  .02).
Men were significantly more likely than women to have
Table II. Number (percent) of people giving affirmative a
1. Have you ever had a blood clot in your legs or lungs? (3)
2. Do you have a family history of blood clots in the veins? (3)
3. Do you currently or have you ever had swollen legs? (1)
4. Do you have visible varicose veins other than spider veins? (1)
5. Do you have ileitis, Crohn’s, or inflammatory bowel disease? (
6. Do you have serious lung disease or emphysema? (1)
7. Within the last month, have you had 3 days of continuous b
8. Within the last month, have you had a pelvic fracture or a plas
9. Do you have or have you had a malignant disease (cancer)? (2
10. Do you weigh 250 pounds? (1)
11. Age between 40 to 59? (1)
12. Age between 60 to 69? (2)
13. Age 70? (3)
Women only
14. Do you take birth control pills or estrogen (hormone) replace
15. Are you pregnant or given birth within the last month? (1)
*Number in parentheses after each question represents points assigned if an
Fig 2. Percentage of participants having each point total in the
score calculation of risk of deep venous thrombosis if placed in a
high-risk situation such as surgical procedure, major injury or other
hospitalizations, malignancy, or prolonged immobility.popliteal vein reflux (P  .002).When comparing different cohort groups with the
DVT risk score grouped as low/moderate risk vs high/very
high risk, African Americans were significantly less likely to
be in the high/very high risk group compared with Cauca-
sians (P .02). Participants with hypertension were signif-
icantly more likely to be in the high/very high risk for DVT
compared with those without hypertension (P  .03).
An examination of differences in cohort groups with
respect to clinical classification of CVI demonstrated that
clinical class was significantly lower in African Americans
compared with all others (P  .02). Similarly, increasing
age and increasing DVT risk score significantly correlated
with increasing clinical classification, r 0.09, P .04 and
r  0.16, P  .0004, respectively. Those participants with
reflux in one or more segments were significantly more
likely to have a higher clinical classification compared with
those with no reflux, P  .0001.
DISCUSSION
Themission of the first National Screening Program for
Venous Disease created by the American Venous Forum in
concert with the American Vascular Association was to
educate, identify, and empower people with knowledge
Table III. Number (percent) of abnormal findings of
obstruction or reflux in the common femoral vein,
saphenofemoral junction, and popliteal vein of each
extremity
Obstruction Right n (%) Left n (%)
Common femoral vein 5 (1) 1 (0.2)
Saphenofemoral junction 4 (1) 1 (0.2)
Popliteal vein 9 (2) 2 (0.4)
Reflux
Common femoral vein 56 (12) 54 (11)
Saphenofemoral junction 78 (16) 83 (17)
Popliteal vein 34 (7) 49 (10)
rs to questions assessing venous thromboembolism risk*
Number (%)
59 (12)
105 (22)
128 (27)
395 (82)
33 (7)
16 (3)
st due to injury or illness? (1) 15 (3)
g cast? (1) 0 (0)
48 (10)
30 (6)
223 (47)
113 (24)
120 (25)
therapy? (1) 66 (14)
1 (0.2)
ative answer was given. Points were added for a risk score.nswe
1)
ed re
ter le
)
mentabout common venous problems affecting themselves and
is) we
JOURNAL OF VASCULAR SURGERY
January 2007146 McLafferty et alothers. In doing so, a major goal of the study was to
develop a program that was comprehensive yet streamlined.
The four parts of the screening process included comple-
tion of a DVT risk factor assessment, abbreviated duplex
examination, inspection of the legs for signs of CVI, and an
exit interview with a physician or trained allied health
professional. Participants received a report card that they
were encouraged to share with their primary care providers.
Additional education materials about DVT, varicose veins,
and CVI were given to those being screened at no charge.
Although free venous screenings for varicose veins
and telangiectasias are relatively common among spe-
cialty vein centers, the National Screening Program for
Venous Disease sought to be as complete as possible in
covering the spectrum of venous disease while at the
same time remaining consistent and streamlined. Con-
sidering the scope of venous disease, designing an ideal
screening program remains difficult. As outlined in the
“Methods” section, much deliberation from experts in
venous disease from the American Venous Forum led to
a process that would address VTE and CVI. The major
focus of the process, modeled after the arterial screening
process from the American Vascular Association, was to
increase public education and awareness. The risk assess-
ment, abbreviated duplex ultrasound examination, clin-
ical inspection, and exit interview with report card all
contribute to the educational experience of the partici-
pant.
A total of 77% of the participants were classified as
high risk (5% to 10%) or very high risk (10% to 20%) for
developing a DVT if placed in a situation at high risk for
thrombosis. At first glance, this finding may appear to be
too high when considering the general population.
Closer scrutiny shows that this percentage may indeed be
accurate considering the population that was screened in
this pilot program. The demographic data indicate that
our population was older (mean age, 60 years), over-
weight (68% with BMI of 25), and had more comor-
bidities than would have been observed from a more
random selection of people closer to the middle age
years.
The medical literature is laden with situations that
increase the risk of DVT with no or varying degrees of
prophylaxis.15 Without prophylaxis, the risk of DVT
Table IV. Number (percent) of extremities in each clinica
Class 0 No visible or palpable signs of venou
Class 1 Telangiectases, reticular veins, malleo
Class 2 Varicose veins
Class 3 Edema without skin changes
Class 4* Skin changes ascribed to venous disea
Class 5 Skin changes† with healed ulceration
Class 6 Skin changes† with active ulceration
*Class 4a (pigmentation, venous eczema) and Class 4b (lipodermatoscleros
†Skin changes as defined in class 4.when patients are put in a high-risk situation, such assustained head injury or total hip replacement, can be
even higher than those quoted from our own risk assess-
ment. Furthermore, correct prophylaxis as directed from
the American College of Chest Physicians16 is not guar-
anteed given the variations in physician compliance and
practice habits.17-18 Educating the public about the risk
of DVT when in a high-risk situation therefore becomes
paramount to providing the necessary step to remind
physicians to be more aware of these risks. Additional
education about what constitutes a high-risk situation is
as equally important in this mission of prevention.
Forty percent of participants had evidence of venous
valve reflux of0.5 seconds. This abbreviated examination
is a variation of that previously described by van Bemmelen
et al.19 The method use during the screening process was to
put the person in the supine position with the head of the
bed elevated 30° to 45°. The segments were identified by
duplex imaging, and a Valsalva maneuver was then per-
formed to demonstrate reflux. As stated in the report by van
Bemmelen et al, the Valsalva maneuver can be hindered by
the presence of iliofemoral valves, and therefore, one could
infer from this study that potentially40% of people could
have had venous reflux in one or more segments.
The automated cuff deflation test with the person in
the standing position was not practical because of time
constraints in providing for an abbreviated streamlined
screening process. More work will be needed in the form
of an audit to determine variability of the duplex ultra-
sound screening from site to site. Despite a level of
presumed variability, the correspondence of reflux to
clinical classification further validates the abbreviated
duplex examination performed during screening. Signs
of CVI were very common in the population screened.
One in three people had varicose veins, and one in five
had a clinical classification score of 3. Considering the
morbidity from CVI, education about measures to help
prevent and treat these conditions could have a profound
impact on those people at risk.
The National Venous Screening Program is not a pro-
gram designed to give intricate details about the complex
physiology of venous valvular reflux and findings of ob-
struction. We admonish that individual trends in valvular
reflux and a thorough examination for obstruction from a
screening examinationmay not indicate a complete picture.
s of chronic venous insufficiency
Right n (%) Left n (%)
ase 87 (19) 91 (20)
re 171 (37) 170 (37)
129 (28) 122 (26)
45 (10) 48 (10)
30 (6) 29 (6)
3 (0.6) 3 (0.6)
1 (0.2) 1 (0.2)
re combined into one category for the venous screening.l clas
s dise
lar fla
seEmphasis should be placed on the fact that the abbreviated
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reflux does not relay information about other areas that are
insonated during a complete examination, hence screening
participants could have positive findings in other areas. The
hope of the screening program is to identify in a quick and
cohesive way whether a person may have reflux in a limb.
The three sites in each limb (CFV, above knee popliteal
vein, and SFJ) were chosen because of their importance and
their ease of duplex examination by the method previously
described.
Despite correlation of the abbreviated screening duplex
exam to clinical classification in this screening population,
more work is needed to correlate the abbreviated screening
duplex examination to the comprehensive examination as
described by van Bemmelen et al.19 Given that the abbre-
viated screening duplex examination could yield a false-
negative examination and the screening participant could
have physical signs of venous obstruction or insufficiency,
the hope of the National Venous Screening Program is that
the screening participant will give the report card to the
primary care physician, who will in turn conduct a detailed
reflux examination or refer to a specialist who will conduct
a more detailed reflux examination performed in the stand-
ing position with cuff deflation.
The selection of participants in this first national venous
screening pilot project was not random and, overall, they
represented a small cohort. Sites were advised to screen
adults aged 40 years, and those who finally responded to
advertising to participate in the screening were a select
group. Not surprisingly, this screening process revealed a
very high rate of positive findings for venous disease. In
contrast, although the public may be aware of venous
disease, they may not be generally privy to the devastating
risks of VTE and the potential morbidity of CVI. Thus, the
screening further verifies the commonality of DVT risk,
varicose veins, and CVI by the findings herein. Critically
needed in this commonality is public awareness and foster-
ing public responsibility in prevention of these potentially
serious problems. The exit interview with a physician or
allied health professional in combination with a report card
to share with the participants’ primary care provider begin
the foundation for building a national paradigm of im-
proved health through public education and empower-
ment.
More work is needed, and the National Venous
Screening program hopes to expand to more centers in
the future. Balance is required in improving the National
Venous Screening program, and the effectiveness of
screening is often at odds with mechanics and feasibility
of screening. Nevertheless, adding a venous disability
score or an abbreviated quality-of-life questionnaire may
improve the screening process and further validate the
instrument. Other goals include providing participants
with more educational materials, linking screenings with
awareness campaigns directed to physicians, continuing
to build sponsorship, and performing a cost-effectiveness
analysis. This first pilot program was feasible due to a
generous grant from the Juzo Company (Aichach, Ger-many); however, all screening materials were void of any
link to industry sponsors.
CONCLUSION
Physicians and allied health professionals who are capa-
ble of meeting the requirements of performing a venous
screening are encouraged to participate and offer this pub-
lic health service to their community. A single day of free
screening to the public for venous disease seems little to ask
when one considers the scope of venous disease and the
sorely needed beginning of preventative medicine in the
United States.
We thankMichele Lentz for her tireless commitment to
the National Venous Screening Program.
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List of centers participating in the National Pilot
Screening Program for Venous Disease by state and their
coordinators
Arizona: Morrison Vein Institute, Tempe, Valerie Killip
Florida: Anchor Vascular Surgery, Naples, Hiranya Ra-
jasinghe, MD
Illinois: SIU School of Medicine, Springfield, Robert
McLafferty, MD
Indiana: IU Vascular Diagnostic Center, Indianapolis,
Debra Hinchman, BS, RVT
Michigan: University of Michigan Health System, Ann
Arbor, Sandy Brown; Comprehensive Vascular Care,
Southfield, Linda Myers; University of Michigan Medical
Center, Ann Arbor, Thomas Wakefield, MD; Vein and
Vascular Clinic of Lansing, Lansing, Graham Kelly, MDMississippi: River Oaks Health System, Jackson, Emily
Myers
North Carolina: Vein Clinic of NC/Forsyth Medical
Center, Winston-Salem, Susan Martin
New York: University Hospital at Stony Brook, Stony
Brook, Antonios Gasparis, MD; Vascular Institute of New
York, Brooklyn, Natalie Marks
Ohio: The Cleveland Clinic Foundation, Cleveland,
Matthew Eagleton, MD; Good Samaritan Hospital, Cin-
cinnati, Sue Polaski
South Carolina: Carolina Vascular Surgery, Rock Hill,
Tracie Dauplaise, RVT
Tennessee: Vascular Center/Vanderbilt University
Medical Center, Nashville, Marc Passman, MD
Virginia: Rockingham Memorial Hospital, Harrison-
burg, Helen Simmons
